Sun Pharma Surges By 5%; BSE Healthcare Index Up 0.9%

SUN PHARMA share price has zoomed 5% and is presently trading at Rs 420.

Meanwhile, the BSE HEALTHCARE Index is at 13,967 (up 0.9%).

Among the top Gainers in the BSE HEALTHCARE Index today are SUN PHARMA (up 5.3%) and SUN PHARMA ADV. RES. (up 7.2%).

ABBOTT INDIA and WOCKHARDT LTD. are among the top losers today.

Over the last one year, SUN PHARMA has moved down from Rs 576 to Rs 420, registering a loss of Rs 156 (down 27.2%).

On the other hand, the BSE HEALTHCARE has moved down from 14,966 to 13,967, loss of 999 points (down 6.7%) during the last 12 months.

The top gainers among the BSE HEALTHCARE Index stocks during this same period were ABBOTT INDIA (up 49.0%), DIVIS LABORATORIES (up 40.0%) and SANOFI INDIA (up 36.4%).

What About the Benchmark Indices?

The BSE Sensex is at 36,650 (down 0.4%).

The top gainers among the BSE Sensex stocks today are SUN PHARMA (up 5.3%), KOTAK MAH. BANK (up 2.9%) and BAJAJ FINANCE (up 1.1%). Other gainers include ONGC (up 0.2%) and BHARTI AIRTEL (up 0.1%). The most traded stocks in the BSE Sensex are SUN PHARMA and KOTAK MAH. BANK.

In the meantime, NSE Nifty is at 10,950 (down 0.4%). SUN PHARMA (up 5.4%) and KOTAK MAH. BANK (up 3.0%) are among the top gainers in NSE Nifty.

Over the last 12 months, the BSE Sensex has moved up from 35,798 to 36,650, registering a gain of 852 points (up 1.8%).

SUN PHARMA Financial Update...

SUN PHARMA net profit down at Rs 1 billion for the quarter ended September 2018, compared to a loss of Rs 4 billion a year ago. Net Sales rose 4.3% to Rs 69.4 billion during the period as against Rs 66.5 billion in July-September 2017.

For the year ended March 2018, SUN PHARMA reported 54.3% decrease in net profit to Rs 35.8 billion compared to net profit of Rs 78.4 billion during FY17.

Revenue of the company grew 16.1% to Rs 265 billion during FY18.

The current Price to earnings ratio of SUN PHARMA, based on rolling 12 month earnings, stands at 34.1x.

Disclosure: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. ...

more
How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.